SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Hedenfalk Ingrid) "

Search: WFRF:(Hedenfalk Ingrid)

  • Result 81-85 of 85
Sort/group result
   
EnumerationReferenceCoverFind
81.
  • Strand, Carina, et al. (author)
  • Combination of the proliferation marker cyclin A, histological grade, and estrogen receptor status in a new variable with high prognostic impact in breast cancer
  • 2012
  • In: Breast Cancer Research and Treatment. - : Springer Science and Business Media LLC. - 0167-6806 .- 1573-7217. ; 131:1, s. 33-40
  • Journal article (peer-reviewed)abstract
    • Global gene expression profiles, consisting mainly of genes associated with proliferation, have been shown to subdivide histological grade 2 breast cancers into groups with different prognosis. We raised the question whether this subdivision could be done using a single proliferation marker, cyclin A. Furthermore, we combined cyclin A (CA), histological grade (G), and estrogen receptor-ER (E) into a new variable, CAGE. Our aim was to investigate not only the prognostic importance of cyclin A alone but also the value of the combination variable CAGE. In 219 premenopausal node-negative patients, cyclin A was assessed using immunohistochemistry on tissue microarrays. High cyclin A was defined as above the seventh decile of positive cells. Only 13% of the patients received adjuvant systemic therapy. Cox proportional hazards regression was used to model the impact of the factors on distant disease-free survival (DDFS). Cyclin A divided histological grade 2 tumors into two groups with significantly different DDFS (hazard ratio [HR]: 15, P < 0.001). When stratifying for ER status, cyclin A was a prognostic factor only in the ER positive subgroup. We found that CAGE was an independent prognostic factor for DDFS in multivariate analysis (HR: 4.1, P = 0.002), together with HER2. CAGE and HER2 identified 53% as low-risk patients with a 5-year DDFS of 95%. A new prognostic variable was created by combining cyclin A, histological grade, and ER (CAGE). CAGE together with HER2 identified a large low-risk group for whom adjuvant chemotherapy will have limited efficacy and may be avoided.
  •  
82.
  • Strand, Carina, et al. (author)
  • The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naive women with N0/N1 primary breast cancer
  • 2013
  • In: SpringerPlus. - : Springer Science and Business Media LLC. - 2193-1801. ; 2
  • Journal article (peer-reviewed)abstract
    • Background: The aim was to confirm a previously defined prognostic index, combining a proliferation marker, histological grade, and estrogen receptor (ER) in different subsets of primary N0/N1 chemo-naive breast cancer patients. Methods/design: In the present study, including 1,854 patients, Ki67 was used in the index (KiGE), since it is the generally accepted proliferation marker in clinical routine. The low KiGE-group was defined as histological grade 1 patients and grade 2 patients which were ER-positive and had low Ki67 expression. All other patients made up the high KiGE-group. The KiGE-index separated patients into two groups with different prognosis. In multivariate analysis, KiGE was significantly associated with disease-free survival, when adjusted for age at diagnosis, tumor size and adjuvant endocrine treatment (hazard ratio: 3.5, 95% confidence interval: 2.6-4.7, P<0.0001). Discussion: We have confirmed a prognostic index based on a proliferation marker (Ki67), histological grade, and ER for identification of a low-risk group of patients with N0/N1 primary breast cancer. For this low-risk group constituting 57% of the patients, with a five-year distant disease-free survival of 92%, adjuvant chemotherapy will have limited effect and may be avoided.
  •  
83.
  • Tabariès, Sébastien, et al. (author)
  • Afadin cooperates with Claudin-2 to promote breast cancer metastasis
  • 2019
  • In: Genes & Development. - : Cold Spring Harbor Laboratory. - 1549-5477 .- 0890-9369. ; 33:3-4, s. 180-193
  • Journal article (peer-reviewed)abstract
    • Claudin-2 promotes breast cancer liver metastasis by enabling seeding and early cancer cell survival. We now demonstrate that the PDZ-binding motif of Claudin-2 is necessary for anchorage-independent growth of cancer cells and is required for liver metastasis. Several PDZ domain-containing proteins were identified that interact with the PDZ-binding motif of Claudin-2 in liver metastatic breast cancer cells, including Afadin, Arhgap21, Pdlim2, Pdlim7, Rims2, Scrib, and ZO-1. We specifically examined the role of Afadin as a potential Claudin-2-interacting partner that promotes breast cancer liver metastasis. Afadin associates with Claudin-2, an interaction that requires the PDZ-binding motif of Claudin-2. Loss of Afadin also impairs the ability of breast cancer cells to form colonies in soft agar and metastasize to the lungs or liver. Immunohistochemical analysis of Claudin-2 and/or Afadin expression in 206 metastatic breast cancer tumors revealed that high levels of both Claudin-2 and Afadin in primary tumors were associated with poor disease-specific survival, relapse-free survival, lung-specific relapse, and liver-specific relapse. Our findings indicate that signaling downstream from a Claudin-2/Afadin complex enables the efficient formation of breast cancer metastases. Moreover, combining Claudin-2 and Afadin as prognostic markers better predicts the potential of breast cancer to metastasize to soft tissues.
  •  
84.
  • Veerla, Srinivas, et al. (author)
  • Deciphering the normal-like molecular subtype of breast cancer
  • 2023
  • Conference paper (other academic/artistic)abstract
    • The normal-like molecular subtype of breast cancer has not been well characterized and is currently not included in the clinically approved PAM50 molecular subtype classification. Tumors classified as normallike display high expression of basal epithelial genes and low expression of luminal epithelial genes, but also high expression of genes expressed by non-epithelial cell types including adipocytes [1]. The normal-like subtype has been suggested to represent tumors with low invasive tumor cell content, hence challenging its legitimacy as an intrinsic subtype. To clarify this issue we aimed to characterize the features of early breast cancers classified as normal-like using RNA sequencing and immunohistochemistry (IHC). Using a consecutive series of 14,000 early breast cancers from the population-based multi-center observational Sweden Cancerome Analysis Network – Breast (SCAN-B)and a recently published RNAseq-based single-sample molecular subtype predictor [2] the subtype distribution was: 39% luminal A, 25% luminal B, 12% HER2-enriched, 9% basal and 15% normal-like. The median tumor size did not differ significantly between the subtypes, while tumor cellularity assessedon H&E slides was lower among normal-like breast cancers (median 20%) compared to the other subtypes (median range 40-70%). Using a version of the classifier that excludes the normal-like subtype, i.e. akin to clinical PAM50 subtyping, 67.5% of the tumors classified as normal-like were reclassifiedas luminal A, with the remaining cases re-classified as either basal (17.5%) or HER2-enriched (14.9%). The distribution of hallmark features among normal-like tumors was 75% ER+, 67% PR+, 20% Ki67 high and 10% HER2 positive by IHC/CISH. IHC further revealed loss of E-cadherin in 30% of normal-like breast cancers, in line with 30% lobular histology. Significantly differentially expressed genes between lobular and non-lobular normal-like breast cancers included CDH1, PGC, CPB1, SERPINA6, TRH, MSLN, MMP1 and AKR1B15. The lobular normal-like breast cancers were enriched for the ER+/HER2- /node negative clinical subgroup (58%). Mutation calling using the SCAN-B MutationExplorer application [3] revealed enrichment of PIK3CA (46% vs. 18%), CDH1 (37% vs. 18%), TP53 (7% vs 0%) and ESR1 (6% vs. 0%) mutations in normal-like lobular vs. luminal lobular breast cancers. Finally, overall survival within the normal-like group was significantly different from all other subtypes and was intermediatebetween the luminal A and B groups (p<0.05 for pairwise comparisons). To conclude, the normal-like subgroup is enriched for lobular breast cancers and displays downregulation of genes involved in cell adhesion and hormone regulation. Normal-like breast cancers are primarily classified as luminal A tumorswith current clinical subtype classification algorithms, but the inferior survival and distinct features of these tumors do not preclude that this may be a true intrinsic subtype, thus warranting further investigation of the normal-like subtype.
  •  
85.
  • Åström, Fredrik, et al. (author)
  • Effects of Research Funding, Gender and Type of Position on Research Collaboration Networks: A Micro-level Study of Cancer Research at Lund University
  • 2013
  • In: PROCEEDINGS OF ISSI 2013 Vienna: 14th International Society of Scientometrics and Informetrics Conference. - 2175-1935. - 9783200031357 ; , s. 677-689
  • Conference paper (peer-reviewed)abstract
    • The aim of this study is to analyse the extent of which different types of research funding, gender and type of position have an effect on the size and density of research collaboration networks. The material consists of 3,306 documents by scientists doing cancer research at Lund University, indexed in the Web of Science databases. The author and address fields were analysed, by studying frequencies and distribution of authors and organizations, and by conducting co-authorship analyses on the organizational level. The results show substantial differences between scientists with funding from the Swedish Cancer Society (SCS) in comparison with those without SCS funding. When comparing men and women, as well as scientists with preclinical positions and those combining clinical and pre-clinical work; there are larger differences between e.g. women with or without SCS funding than between men and women with SCS funding. The general applicability of these results might be limited; they only take one certain kind of funding into account and they analyses are performed on documents coming out of one particular context. In this case, however, the results suggest that research funding have a larger impact on the size and nature of research collaboration networks than gender or type of position.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 81-85 of 85
Type of publication
journal article (68)
conference paper (7)
research review (5)
doctoral thesis (2)
book chapter (2)
reports (1)
show more...
show less...
Type of content
peer-reviewed (76)
other academic/artistic (9)
Author/Editor
Hedenfalk, Ingrid (81)
Kimbung, Siker (17)
Johansson, Ida (15)
Loman, Niklas (12)
Bendahl, Pär Ola (11)
Fjällskog, Marie Lou ... (11)
show more...
Veerla, Srinivas (11)
Malander, Susanne (11)
Ebbesson, Anna (10)
Nilsson, Cecilia (10)
Borg, Åke (10)
Måsbäck, Anna (10)
Hatschek, Thomas (10)
Fernö, Mårten (9)
Olsson, Håkan (8)
Ringnér, Markus (8)
Martin de la Fuente, ... (7)
Jönsson, Jenny Maria (7)
Malmström, Per (6)
Rydén, Lisa (6)
Borgquist, Signe (6)
Vallon-Christersson, ... (6)
Nilbert, Mef (6)
Grabau, Dorthe (6)
Kannisto, Päivi (6)
Bergh, Jonas (5)
Jirström, Karin (5)
Staaf, Johan (5)
Westbom-Fremer, Sofi ... (5)
Berglund, Pontus (5)
Forsare, Carina (5)
Ehinger, Anna (4)
Honeth, Gabriella (4)
Arildsen, Nicolai Sk ... (4)
Hegardt, Cecilia (4)
Rennstam, Karin (4)
Aaltonen, Kristina (3)
Landberg, Göran (3)
Ahlin, Cecilia (3)
Larsson, Christer (3)
Hagerling, Catharina (3)
Einbeigi, Zakaria, 1 ... (3)
Danielsson, Anna, 19 ... (3)
Bergkvist, Leif (3)
Hedenfalk, Ingrid A. (3)
Lauss, Martin (3)
Luts, Lena (3)
Malmberg, Martin (3)
Bjarnadottir, Olöf (3)
Bååth, Maria (3)
show less...
University
Lund University (84)
Karolinska Institutet (16)
Uppsala University (14)
University of Gothenburg (6)
Linköping University (6)
Örebro University (2)
show more...
Karlstad University (1)
show less...
Language
English (84)
Swedish (1)
Research subject (UKÄ/SCB)
Medical and Health Sciences (85)
Natural sciences (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view